Japan's eisai inc, said it was voluntarily withdrawing the drug, belviq however, the company said in a. Belviq japan. Eisai reported belviq sales of ¥3,558m ($315m) in the us and ¥4,769m ($422m) in japan for the fiscal year ending march 31 kramer suggested investors may see better sales in the first quarter of the current fiscal year, which will be reported on aug 1.
belviq japan
Belviq is one of five fda-approved weight loss drugs on the market it was never approved for use in canada, as the company could not address some questions the canadian health regulators had in 2013 consumer reports recommended people skip the drug, pointing out that the fda initially rejected belviq because "of a risk of tumors found in. In 2009, belviq’s japanese producer asked the fda to approve lorcaserin for sale in the united states. an advisory panel rejected the application, concluding that the drug’s dangerous side effects outweighed its rather low weight loss potential.. Lorcaserin, marketed under the brand name belviq is a weight-loss drug developed by arena pharmaceuticals.it reduces appetite by activating a type of serotonin receptor known as the 5-ht 2c receptor in a region of the brain called the hypothalamus, which is known to control appetite. it was removed from the market in the united states in 2020 due to its increased risk of cancer..
0 comments:
Post a Comment
Note: Only a member of this blog may post a comment.